- Company
- Celltrion discloses interim results of global phase 3 Eylea
- by Hwang, Jin-joon Apr 5, 2023 05:45am
- On the 3rd, Celltrion disclosed the interim results based on the 24th week of the global phase 3 clinical trial of CT-P42, an eye disease treatment Eylea biosimilar. Celltrion is conducting clinical trials for 52 weeks on 348 DME patients in 13 countries, including Germany and Spain. The interim results released this time are the results of c
- Company
- CHMP gave a positive opinion on the approval of Soliris
- by Jung, Sae-Im Apr 5, 2023 05:44am
- On the 31st of last month, Samsung Bioepis announced that it had obtained a positive opinion for the item approval of 'EPYSQLITM (Eculizumab)', a treatment for rare diseases, from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA). EPYSQLITM is a biosimilar of Alexion's paroxysmal nocturnal hem
- Company
- Hanmi internationally introduces 7 new drug candidates
- by Hwang, Jin-joon Apr 4, 2023 05:53am
- Hanmi Pharmaceutical is revealing its messenger ribonucleic acid (mRNA) cancer vaccine and new targeted anticancer lead compounds. The company reinforced its anticancer pipeline by adding next-generation anticancer drug technologies and targets to its existing major anticancer drug pipeline that has been making smooth progress in preclinical
- Company
- Medytox paid service fees of KRW 97.7B in 4 years
- by Kim, Jin-Gu Apr 4, 2023 05:52am
- The service fees paid out by Medytox during the past 4 years have reached nearly KRW 100 billion. Since 2019, disputes related to botulinum toxin had risen simultaneously in the United States and Korea, which led to an increase in the litigation costs and fees the company has spent. The amount of annual service fee payouts decreased afte
- Company
- Pharma companies face the crisis ‘head-on'
- by Chon, Seung-Hyun Apr 3, 2023 05:49am
- The major listed pharmaceutical and bio companies were found to have significantly increased their R&D personnel over the past 3 years, during the COVID-19 pandemic. 9 out of 10 companies increased their research personnel, and the number increased by 25% during the past 3 years. According to the Financial Supervisory Service on the 31st, the
- Company
- Hugel appoints Seok-yong Cha, former CEO
- by Lee, Seok-Jun Apr 3, 2023 05:49am
- Hugel announced on the 31st that the 22nd regular general meeting of shareholders and board of directors was held and that former vice chairman of LG H&H, another non-executive director Seok-yong Cha was appointed as Hugel's new chairman and chairman of the board of directors. Chairman Cha Seok-yong served as the CEO of LG Household & Health
- Company
- AstraZeneca appoints Suyeon Kim as head of AZ Singapore
- by Eo, Yun-Ho Apr 3, 2023 05:49am
- AstraZeneca has appointed Suyeon Kim (49) from AstraZeneca Korea as General Manager of AstraZeneca Singapore. Suyeon Kim, who has been serving as the Head of the International Oncology Franchise at AstraZeneca, officially took office as General Manager on the 27th of last month. After entering Pfizer Korea as a marketing representa
- Company
- 4 out of 5 biopharmaceuticals increased exports
- by Kim, Jin-Gu Apr 3, 2023 05:49am
- Annual exports of individual pharmaceutical bio companies exceeded 2 trillion won. Last year, Samsung BioLogics recorded exports of 2.8 trillion won, up 2.3 times from the previous year, and Celltrion is also on the verge of achieving 2 trillion won. Of the 30 major listed biopharmaceutical companies, 24 showed an increase in export performance
- Company
- Bladder cancer drugs/new mechanisms appear one after another
- by Eo, Yun-Ho Mar 31, 2023 06:09am
- New treatment options for urothelial cancer are emerging one after another. Domestic commercialization of new drugs such as targeted anticancer drugs and antibody-drug conjugates (ADCs) is underway. Janssen's Balversa, which was approved at the end of last year, is suitable for patients with metastatic urinary tract disease with FGFR2 or 3 mu
- Company
- Generic for Godex development has come to an all-stop
- by Nho, Byung Chul Mar 31, 2023 06:09am
- As pharmaceutical companies preparing to release generics for Godex announced that they would give up development, Celltrion Pharm is expected to dominate. According to the industry, about three pharmaceutical companies have been identified that are preparing generics for Godex, but drug development has been suspended due to development di
